Coherus Oncology (CHRS) Financial Statements & Analysis

Coherus Oncology (CHRS) Income Statement

Coherus Oncology reported revenue of $42.17M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 59.8% from $26.39M a year earlier. Net income was $168.02M, down 38.3% year over year, a net margin of 398.4%. Gross margin was 67.2% and operating margin -429.5%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $14.31M, up 39.5% from the same quarter a year earlier.

Coherus Oncology Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Coherus Oncology, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	42.17	26.39	257.24	211.04	326.55	475.82	356.07	1.56	1.56
Cost of Revenue	13.81	8.73	158.99	70.08	57.59	37.67	17.08	3.24	160.53
Gross Profit	28.36	17.66	98.25	140.96	268.96	438.16	338.99	-1.68	-158.98
Operating Expenses
Research & Development	108.89	91.83	109.44	199.36	363.11	142.76	94.19	110.24	162.39
Selling, General & Administrative	100.60	114.88	192.02	198.48	169.71	139.08	137.04	94.18	71.30
Operating Expenses	209.49	217.32	301.45	397.84	532.82	281.84	231.23	204.42	233.69
Operating Income	-181.13	-199.65	-203.20	-256.88	-263.86	156.32	107.77	-204.42	-232.14
Other Income/Expense
Interest Income	0.00	4.50	0.00	0.00	0.00	0.60	0.00	0.00	0.00
Interest Expense	9.00	-27.16	40.54	32.47	22.96	-21.17	17.60	9.68	9.55
Other Income/Expense	7.01	-15.74	5.47	-2.40	-23.24	-0.05	-14.99	-4.99	-6.15
Income
Income Before Tax	-183.12	-215.39	-238.27	-291.75	-287.10	135.71	92.78	-209.41	-238.29
Income Tax Expense	0.00	0.00	-0.38	0.00	0.00	3.46	2.94	0.00	0.00
Net Income	168.02	272.41	-237.89	-291.75	-287.10	132.24	89.83	-209.34	-238.17
Net Income - Continuous Operations	-183.12	28.51	-237.89	-291.75	-287.10	132.24	89.83	-209.34	-238.17
Net Income - Discontinued Operations	351.15	243.90	-	-	-	-	-	-	-
EBITDA	-170.20	-183.78	-193.94	-255.58	-260.69	159.21	111.03	-204.42	-225.34
EBIT	-174.12	-189.05	-197.73	-259.28	-263.86	156.32	-	-	-
Depreciation & Amortization	3.92	5.28	3.79	3.70	3.45	2.89	3.26	3.24	3.40
Earnings Per Share
Basic EPS	1.00	-	-3.00	-4.00	-4.00	2.00	1.00	-3.00	-4.00
Diluted EPS	1.00	-	-3.00	-4.00	-4.00	2.00	1.00	-3.00	-4.00
Basic Shares Outstanding	117.14	114.55	94.16	77.63	75.45	71.41	69.68	65.01	53.13
Diluted Shares Outstanding	117.14	114.55	94.16	77.63	75.45	83.49	73.19	65.03	53.13

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Coherus Oncology Financial Statements

What was Coherus Oncology's revenue in fiscal 2025?

Coherus Oncology reported revenue of $42.17M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 59.8% from $26.39M a year earlier.

Is Coherus Oncology profitable?

Yes. Coherus Oncology earned net income of $168.02M in fiscal 2025, a net margin of 398.4%. In fiscal 2024 it earned $272.41M.

What is Coherus Oncology's operating margin?

Coherus Oncology's operating income was −$181.13M on revenue of $42.17M in fiscal 2025, an operating margin of -429.5%, compared with -756.6% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition